Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Open Access
- 1 September 2019
- journal article
- review article
- Published by Elsevier in Genes & Diseases
- Vol. 6 (3) , 232-246
Abstract
No abstract availableKeywords
Funding Information
- V Foundation for Cancer Research (V2018-023)
This publication has 157 references indexed in Scilit:
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Regulation and function of mTOR signalling in T cell fate decisionsNature Reviews Immunology, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaNew England Journal of Medicine, 2012
- Single dose of anti–CTLA-4 enhances CD8 + T-cell memory formation, function, and maintenanceProceedings of the National Academy of Sciences, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 2010
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- On the Origin of Cancer CellsScience, 1956